Sentinel Lymph Node Biopsy and Nodal Ultrastaging in Colorectal Cancer

Huynh, Kelly; Bilchik, Anton J.

doi:10.1097/ppo.0000000000000093

Cited by 9 publications

(6 citation statements)

References 50 publications

(62 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sentinel lymph node (SLN) mapping is increasingly more present in this debate and comes in halfway between no dissection and systematic lymphadenectomy. SLN represents the standard of care for melanoma, breast cancer and early-stage vulvar cancer, but it is increasingly more interesting in the staging of many other malignancies including gastric cancer, colorectal cancer and more recently, cervical and endometrial tumors (Takeuchi and Kitagawa 2015;Huynh and Bilchik 2015;Jewell et al 2014).…”

Section: Introductionmentioning

confidence: 99%

Sentinel lymph node mapping in patients with stage I endometrial carcinoma: a focus on bilateral mapping identification by comparing radiotracer Tc99m with blue dye versus indocyanine green fluorescent dye

Papadia

Zapardiel²,

Bussi

et al. 2016

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Sentinel lymph node mapping in patients with stage I endometrial carcinoma: a focus on bilateral mapping identification by comparing radiotracer Tc99m with blue dye versus indocyanine green fluorescent dye

Papadia

Zapardiel²,

Bussi

et al. 2016

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

show abstract

“…In colorectal cancer, knowing the status (positive or negative) of the sentinel node does not influence the surgical technique of lymph node dissection as this must be performed completely regardless. However, it may improve the detection of occult disease harboring lymph nodes, leading to increased diagnostic accuracy ( 13 ).…”

Section: Introductionmentioning

confidence: 99%

Role of methylene blue in detecting the sentinel lymph node in colorectal cancer: In vivo vs. ex vivo technique

et al. 2021

View full text Add to dashboard Cite

The identification of sentinel lymph nodes is a valuable oncological method, which aims at mapping lymphatic drainage and has the advantage of correctly staging the disease and assessing prognosis. Lymph node invasion is an important prognostic feature. In colorectal cancer, lymphadenectomy is not influenced by the positive or negative status of the sentinel lymph node. The identification of lymph nodes with possible invasion by staining the primary tumor with methylene blue can lead to improved staging and management. In other words, the consequent administration of neoadjuvant therapy (chemotherapy) to the appropriate patients may result in lower recurrence rates. Thus, the aim of the present study was to use methylene blue to identify the sentinel node/nodes in colorectal cancer and to determine whether the dye-capturing nodes were invaded by the tumor. This is a non-randomized prospective study, in which 26 patients with colon cancer with surgical indication were enrolled. Two types of methods were utilized: in vivo (16 patients) and ex vivo (10 patients). The identification rate was 75% for the in vivo technique and 60% for the ex vivo technique, resulting in a 69.26% overall identification rate. Of 18 patients with sentinel lymph nodes identified using dye, routine histological examination detected metastases in 6 (33.33%) of these patients. In conclusion, further research should be conducted into how the clinical application of sentinel node detection can be employed in colorectal cancer.

show abstract

“…14 In this study most pN0 patients (71%) had a single LN affected. Moreover, although sentinel lymph nodes (SLN) in CRC are still unclear, 15,16 a Dutch study has shown that the molecular staging of SLN using OSNA is a promising tool for predicting the prognosis of CRC patients. 13 Thus, the molecular diagnosis of LN status using OSNA improves the ability to identify patients that may benefit from an additional systemic treatment.…”

Section: Introductionmentioning

confidence: 99%

Molecular Staging of Patients with Colon Cancer. The C-Closer-II Study: A Multicentre Study in Portugal

et al. 2018

View full text Add to dashboard Cite

Introduction: Approximately 20% - 30% of histological lymph node-negative patients with colorectal cancer relapse at five years after surgical treatment. This recurrence is likely due to occult nodal disease undetected by standard histopathological practice which has implications in terms of the clinical management of patients.Material and Methods: Lymph nodes were collected from colectomy specimens. A central section from each lymph node was histologically examined following haematoxylin-eosin staining and the remaining tissue was subjected to OSNA - one step nucleic acid amplification analysis.Results: A total of 1046 lymph nodes from 59 pN0 patients were assessed. Of these, 753 lymph nodes were examined by both methods. The median number of lymph nodes assessed with OSNA - one step nucleic acid amplification was 12 (IQR: 7;16). Among pN0 patients, 17 had OSNA - one step nucleic acid amplification-positive lymph nodes, resulting in a positive molecular staging rate of 28.8% (95% CI: 17.8 - 42.1). Among these patients, 12 (70.59%) were molecular-staged as pN1 and 5 (29.41%) were molecular staged as pN2. The tumour burden of lymph nodes assessed with OSNA - one step nucleic acid amplification ranged from 270 to 17 000 cytokeratin 19 mRNA copies/μL. Most of these patients (88.2%) were found to have lymph nodes with micrometastases only (250 - 4999 copies/μL).Discussion: We provide the results from the first study of the use of the OSNA - one step nucleic acid amplification assay in colorectal cancer patients in Portugal. Our results are in-line with other international studies, showing the improvement on patients’ staging by molecular examination of lymph nodes.Conclusion: In our study, 28.8% of patients with histologically negative lymph nodes were found to have metastatic lymph nodes using OSNA - one step nucleic acid molecular assessment. OSNA - one step nucleic acid assay allows a more accurate staging of patients with colorectal cancer and standardizes lymph node assessment.

show abstract

Sentinel Lymph Node Biopsy and Nodal Ultrastaging in Colorectal Cancer

Cited by 9 publications

References 50 publications

Sentinel lymph node mapping in patients with stage I endometrial carcinoma: a focus on bilateral mapping identification by comparing radiotracer Tc99m with blue dye versus indocyanine green fluorescent dye

Sentinel lymph node mapping in patients with stage I endometrial carcinoma: a focus on bilateral mapping identification by comparing radiotracer Tc99m with blue dye versus indocyanine green fluorescent dye

Role of methylene blue in detecting the sentinel lymph node in colorectal cancer: In vivo vs. ex vivo technique

Molecular Staging of Patients with Colon Cancer. The C-Closer-II Study: A Multicentre Study in Portugal

Contact Info

Product

Resources

About